Colitis ulcerosa: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• NLRP3 0
• NRF2 0
• STAT3 0
• JAK 2
• TNF 2
• IL-23 5
• TLR4 0
• MAPK 0
• PI3K 0
• PPAR 0
• AKT 0
• STING 0
• mTOR 0
• AMPK 0
• IL-6 0
• HIF-1 0
• TP53 0
• COX-2 0
• IL-17 0
• SIRT1 0
• CTNNB1 0
• GLP-1 0
• HMGB1 0
• HSP90 0
• IL-1 0
• CD40 0
• HDAC 1
• MMP-9 0
• GPX4 0
• JNK 0
• YAP 0
• EGFR 0
• CD19 3
• CTLA-4 0
• IL-4 0
• METTL3 0
• PARP 0
• VEGF 0
• BCMA 3
• ERK 0
• FOXP3 0
• MUC1 0
• PINK1 0
• ACE2 0
• G6PD 0
• IL-15 1
• KEAP1 0
• LRRK2 0
• MDM2 0
• PD-1 0
• PD-L1 0
• PKM2 0
• TIGIT 0
• BRD4 0
• CCR5 0
• CD30 0
• EZH2 0
• IL-13 0
• MYC 0
• PDE4 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Microbiota-Ulcerative Colitis INterface: Phage-bacteria-immune interactions at the mucosal level. (MUCIN)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 217 076 EUR· until 2028. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Characterising the molecular and cellular basis of enteric nervous system alterations in the inflamed gut (NeurogENSity)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 206 888 EUR· until 2027. aug.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  A Fibroblast-Targeting Advanced Lead Mitigating Inflammation and Fibrosis in IBD (FIBROLEAD)

  Inolysis Monoprosopi Idiotiki Kefalaiouchiki Etaireia· Melissia Athens, Görögország· EU contribution 150 000 EUR· until 2027. jan.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Unravelling neuroimmune crosstalk to find novel treatment targets for inflammatory bowel disease (UNTANGLED)

  Stichting Amsterdam Umc· Amsterdam, Hollandia· EU contribution 432 468 EUR· until 2028. ápr.· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Interplay of epithelial mechanics and neutrophil activation as a pathomechanism in refractory IBD and colorectal cancer patients (INTERCONNECTIONS)

  Universitatsklinikum Erlangen· Erlangen, Németország· EU contribution 173 847 EUR· until 2026. dec.

• European Commission (Horizon Europe) · HORIZON-RIA

  InnovaTivE in situ 4D biopriNTing for regenerAtion of CoLorEctal mucosa and submucosa (TENTACLE)

  Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat· Wurzburg, Németország· EU contribution 7 555 750 EUR· until 2028. dec.· 6 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Investigating the role of the intercrypt goblet cells in inflammatory bowel diseases. (GAP)

  Universiteit Utrecht· Utrecht, Hollandia· EU contribution 187 624 EUR· until 2026. nov.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseases (FIBROTARGET)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution 5 686 450 EUR· until 2028. márc.· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  SInGle cells iN AuToimmUne inflammatoRy disEases (SIGNATURE)

  Fundacion Publica Andaluza Progreso y Salud M.p.· Sevilla, Spanyolország· EU contribution 2 630 239 EUR· until 2026. dec.· 7 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Impact Of The Gut Microbiota On Host Cells Energy Metabolism: Role In Health And In Inflammatory bowel disease (ENERGISED)

  Sorbonne Universite· Paris, Franciaország· EU contribution 1 999 265 EUR· until 2027. aug.

  The disease is named only in the funder's project summary, not in the title.

10 of 10 running projects, newest first. Listed amounts together: 19,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 25
• Organoids 15
• Mendelian Randomization Analysis 48
• Gene Expression Profiling 76
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 1
• Exome Sequencing 5
• Proteomics 29
• Metabolomics 48
• Mass Spectrometry 5
• Flow Cytometry 8
• Immunohistochemistry 18
• Magnetic Resonance Imaging 10
• Machine Learning 43
• Deep Learning 11
• Cohort Studies 90
• Genome-Wide Association Study 56

• Epithelial CXCL1 tracks clinical remission in inflammatory bowel disease in a disease-specific manner.

  Front Immunol, 2026. júl.

• Spatiotemporally optimized heterotopic transplantation of early-stage small intestinal organoids ameliorates murine ulcerative colitis.

  Int Immunopharmacol, 2026. júl.

• Patient-matched transcriptomics of in vivo and in vitro colonic epithelium substantiate organoids as a translational model for ulcerative colitis.

  Sci Rep, 2026. jún.

• PPARγ controls I3C-mediated anti-inflammatory effects through the NF-κB/IL-6 pathway on gut inflammation models.

  Biomed Pharmacother, 2026. jún.

• Reprogramming gut microenvironment for the treatment of acute severe ulcerative colitis via a synergistic therapy of necroptosis blockade and organoid transplantation.

  Nat Commun, 2026. máj.

• Advancing drug discovery for inflammatory bowel diseases through human intestinal organoid-based models.

  Expert Opin Drug Discov, 2026. ápr.

• CBP phosphorylation maintains intestinal homeostasis by supporting the stem cell niche through versican.

  Nat Commun, 2026. márc.

• IL-22 induces Paneth cell metaplasia in the colonic epithelium of ulcerative colitis, promoting wound healing via REG3A.

  Nat Commun, 2026. márc.

• Intestinal Stem Cells From Patients With Inflammatory Bowel Disease Retain an Epigenetic Memory of Inflammation.

  Cell Mol Gastroenterol Hepatol, 2026. márc.

• The emerging roles of intestinal organoid models in inflammatory bowel disease research.

  Expert Rev Gastroenterol Hepatol, 2026. febr.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.